Edition:
India

Gilead Sciences Inc (GILD.OQ)

GILD.OQ on NASDAQ Stock Exchange Global Select Market

80.95USD
2:29am IST
Change (% chg)

$-0.46 (-0.57%)
Prev Close
$81.41
Open
$81.23
Day's High
$82.18
Day's Low
$80.91
Volume
2,422,495
Avg. Vol
2,662,217
52-wk High
$86.26
52-wk Low
$63.76

Select another date:

Thu, Jan 18 2018

BRIEF-Kite Announces Clinical Collaboration With Pfizer

* KITE ANNOUNCES CLINICAL COLLABORATION TO EVALUATE INVESTIGATIONAL COMBINATION OF YESCARTA™ (AXICABTAGENE CILOLEUCEL) AND PFIZER’S UTOMILUMAB IN LARGE B-CELL LYMPHOMA

Florida man gets prison for trading on tip about Gilead deal

A Florida man was sentenced on Wednesday to one year in prison for engaging in insider trading based on a tip he received from an ex-Morgan Stanley broker about Gilead Sciences Inc's planned $11.2 billion purchase of Pharmasset Inc in 2011, prosecutors said.

Florida man gets prison for trading on tip about Gilead deal

Jan 17 A Florida man was sentenced on Wednesday to one year in prison for engaging in insider trading based on a tip he received from an ex-Morgan Stanley broker about Gilead Sciences Inc's planned $11.2 billion purchase of Pharmasset Inc in 2011, prosecutors said.

BRIEF-Galapagos Exercises Co-Promotion Option For Filgotinib

* SAID ON THURSDAY IT WILL OPT-IN ON CO-PROMOTION OF FILGOTINIB WITH COLLABORATION PARTNER GILEAD SCIENCES IN EIGHT EUROPEAN COUNTRIES, SHOULD FILGOTINIB BE APPROVED FOR COMMERCIAL SALE

Gilead's new drug keeps 56 percent of lymphoma trial patients alive

More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday.

Gilead's new drug keeps 56 percent of lymphoma trial patients alive

More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday.

Gilead's new drug keeps 56 pct of lymphoma trial patients alive

Dec 10 More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday.

Gilead to buy Cell Design Labs for up to $567 million

Drugmaker Gilead Sciences Inc said on Thursday it was acquiring privately-held Cell Design Labs Inc for up to $567 million, giving it access to new technology platforms that would help in the development of cancer drugs.

BRIEF-Gilead Sciences and Kite To Acquire Cell Design Labs

* GILEAD SCIENCES INC - DEAL FOR UP TO APPROXIMATELY $567 MILLION

UPDATE 1-Gilead to buy Cell Design Labs for up to $567 mln

Dec 7 Drugmaker Gilead Sciences Inc said on Thursday it was acquiring privately-held Cell Design Labs Inc for up to $567 million, giving it access to new technology platforms that would help in the development of cancer drugs.

Select another date: